RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX) but has reduced the price target from $7 to $6.

November 10, 2023 | 7:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained its Outperform rating on Viracta Therapeutics but lowered the price target from $7 to $6, indicating a potential upside but with moderated expectations.
The maintenance of an Outperform rating suggests that RBC Capital still sees Viracta Therapeutics as a stock likely to perform better than the broader market. However, the reduction in the price target could reflect a reassessment of the company's near-term growth prospects or market conditions, leading to a neutral short-term impact on the stock price as investors digest the mixed signals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100